8-K: Quest Patent Research Corporation to Restate 2023 Financials Due to $1.37 Million Understatement

Quest Patent Research Corporation will restate its 2023 financial statements after discovering a $1.37 million understatement of litigation and licensing expenses.

Summary

• Quest Patent Research Corporation identified an error in its 2023 financial statements.
• The company understated litigation and licensing expenses by $1,371,109.
• This error occurred due to the failure to include accrued legal fees related to a litigation settlement in the fourth quarter of 2023.
• As a result, the company's gross margin, income from operations, income before income taxes, and net income were all overstated by the same amount.
• The originally reported net income for 2023 was $3,649,582, or $0.68 per share.
• The corrected net income for 2023 is $2,278,473, or $0.43 per share.
• The company's independent auditor concurred with the findings.
• The board of directors has determined that the previously issued financial statements should not be relied upon and will be restated.

Sentiment

Score: 3

Explanation: The document reveals a significant accounting error requiring a restatement, which is a negative development for investors. The magnitude of the error and the need for a restatement are concerning.

Negatives

• The company's 2023 financial statements were materially misstated.
• The company failed to properly account for accrued legal fees.
• The restatement will require additional work and may cause investor concern.

Risks

• The restatement of financial statements could negatively impact investor confidence.
• There is a risk of further errors being discovered in the restated financials.
• The company may face scrutiny from regulators due to the misstatement.

Future Outlook

The company will file an amendment to its Form 10-K for the year ended December 31, 2023, to reflect the restated financials.

Management Comments

• The company's chief executive officer determined that the litigation and licensing expenses for the year ended December 31, 2023 was understated.
• The company's board of directors determined that the financial statements for the year ended December 31, 2023 should not be relied upon and should be restated.

Industry Context

This type of restatement is not uncommon, but it does raise concerns about the company's internal controls and accounting practices. It is important for companies to have robust systems in place to ensure accurate financial reporting.

Comparison to Industry Standards

• While restatements occur across industries, the magnitude of the error, representing a 37.6% overstatement of net income, is significant.
• Companies with strong internal controls and robust accounting practices typically have fewer restatements.
• Comparable companies in the patent research and licensing space would be expected to have similar accounting standards and controls, and a restatement of this magnitude would be considered a negative signal.

Stakeholder Impact

• Shareholders will be impacted by the restatement and the reduction in reported net income.
• The company's reputation may be negatively affected by the accounting error.
• Creditors may be concerned about the company's financial reporting practices.

Next Steps

• The company will file an amendment to its Form 10-K for the year ended December 31, 2023.
• The company will restate its financial statements for the year ended December 31, 2023.

Key Dates

Keywords

financial restatement, accounting error, litigation expenses, legal fees, net income, earnings per share, financial statements, SEC filing